Navigation Links
Michael V. Novinski, Emisphere President/CEO Featured in the Wall Street Transcript
Date:5/16/2008

CEDAR KNOLLS, N.J., May 16 /PRNewswire-FirstCall/ -- Highlighting the company's expectations for the future as well as its current product pipeline, Michael V. Novinski, President and CEO of Emisphere Technologies, Inc. (Nasdaq: EMIS), was featured in an extensive interview published recently in The Wall Street Transcript (TWST). Established more than 40 years ago, TWST interviews the leaders of financial markets, including CEOs, analysts and money managers, and publishes their viewpoints, opinions and recommendations.

In his interview, Mr. Novinski discussed the two most important objectives for the company moving forward: "We want to bring our technology to the commercial level as soon as possible," he said, "and build our early and mid-stage pipeline with additional partnerships, expecting to add three new partnerships during 2008."

Mr. Novinski also explained Emisphere's proprietary eligen(R) technology and its applications for drug delivery to address a number of medical conditions. He said that the technology needs to come from the clinical experimental stage to the commercial level. "At that point we will be able to demonstrate that, in fact, our technology can provide benefits to the population at large, for whatever treatment it is we are talking about," Mr. Novinski explained.

One of those treatments is for Vitamin B12 deficiency. Emisphere has completed two successful animal studies using its eligen(R) technology for an oral formulation of Vitamin B12, and expects to be conducting studies in humans by mid-year, Mr. Novinski told TWST. "We believe there should be an opportunity to commercialize our technology [with our oral Vitamin B12 formulation] as early as next year."

Mr. Novinski also discussed t
'/>"/>

SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
5. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
8. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
9. Genstar Names Michael Hurt to Its Strategic Advisory Board
10. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
11. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 The fully ... (Nexera UC) can sequentially analyze up to 48 ... with high-sensitivity detection of targets by mass spectrometry. ... to fulfill the measurement requirements of a wide ... products, drug delivery and search for disease biomarkers, ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/27/2015)... Francisco, CA (PRWEB) February 27, 2015 ... joining forces on February 28 with patients and health ... raise awareness for Rare Disease Day®. Rare Disease ... diseases and calling attention to the special challenges faced ... around them. , “Cytokinetics is proud to stand alongside ...
(Date:2/27/2015)... Feb. 27, 2015   PureTech , a science ... commercializing disruptive products and technologies in the healthcare sector, ... former CEO and Member of the Board of Directors ... "It,s has been a pleasure to know Chris ... we will be working together more closely now," said ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4
... Therapeutics Inc. (TSX:,LOR, AMEX: LRP) ("Lorus" or ... research and development of pharmaceutical products and,technologies ... progress made in,the Virulizin(R) development program, including ... Virulizin(R) mode of action and the issuance ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... Vice President, Global Supply Chain and,Sustainment Engineering. He ... of Alexza,s global supply chain strategy to,support the ... lead program, AZ-004 (Staccato(R) loxapine) is in,Phase 3 ...
... ... Advisory Board --, SAN DIEGO, July 9 ... has received regulatory approval to,begin a Phase 2a proof-of-concept clinical trial ... arthritis, is a,painful and debilitating disease caused by abnormally elevated levels ...
Cached Biology Technology:Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 3Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 4Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 5Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 6Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering 2Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering 3Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 2Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 3Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 4
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
(Date:1/22/2015)... - Today, FindBiometrics, the leading source of biometrics industry news, interviews ... design. "When we launched FindBiometrics 12 years ago ... , founder and CEO of FindBiometrics. "Now it,s maturing very ... key players on a very broad scale.  We are known ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... potential for an outbreak of the phenomenon commonly called ... spring and summer, according to researchers with the Woods ... (NCSU). This advisory is based in part ... Alexandrium fundyense the algae notorious ...
... international team of researchers from China and the United ... Early Cretaceous rocks in the southern part of the ... Jiayuguan, Gansu Province, China. Two of their discoveries represent ... in technical publications published on-line in the Proceedings ...
... in French . Scientists at the ... Japan along with researchers from McGill University and other ... are controlled in mammals. Three years of intensive research by ... publication of several milestone scientific papers in Nature Genetics ...
Cached Biology News:Researchers report 'moderately large' potential for red tide outbreak in Gulf of Maine region 2Researchers report 'moderately large' potential for red tide outbreak in Gulf of Maine region 3Researchers report 'moderately large' potential for red tide outbreak in Gulf of Maine region 4Field Museum paleontologist leads study on two new dinosaurs from China 2Field Museum paleontologist leads study on two new dinosaurs from China 3Field Museum paleontologist leads study on two new dinosaurs from China 4Major international study challenges notions of how genes are controlled in mammals 2
... early protein. Can detect ... exhibiting an intranuclear inclusion staining ... 6-24 hours. These antibodies ... staining. No other nuclear ...
MAb to Vasopressin Preservative: NaN3...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
Biology Products: